research Drug-Induced Postinfantile Giant Cell Hepatitis
Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
Search
for
Sort by
Research
30 / 1000+ results 
research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research PSS20 Mediation Modeling and Measurement Characteristics of the Itch Severity Score from a Phase 2B Trial of Oral CP-690-550 in Patients with Moderate-to-Severe Plaque Psoriasis
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Non-Clinical Safety Evaluation and Risk Assessment of Aleglitazar, a Dual PPAR α/γ Agonist, and Its Major Human Metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Industry Update: The Latest Developments in the Field of Therapeutic Delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Prostate Cancer Prevention
Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Current Best Evidence in Pigmentary Dermatology
Several treatments are effective for pigmentary disorders like vitiligo and melasma.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Analyses of Patient-Reported Outcomes with Mirvetuximab Soravtansine Versus Standard Chemotherapy in the Randomized Phase III FORWARD I Study in Ovarian Cancer
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Janus Kinase Inhibitors in Dermatology: A Systematic Review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Androgens and Acne: Perspectives on Clascoterone, the First Topical Androgen Receptor Antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Dupilumab: A Review of Present Indications and Off-Label Uses
Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
research Baricitinib: From Rheumatoid Arthritis to COVID-19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.